Brought to you by:
BEST-CLI and the BASIL trials: Motion sees audience move in favor of endovascular therapy over bypass
During the 2024 Charing Cross (CX) International Symposium in London, England (April 23–25), a Great Debate that pitted four global peripheral arterial disease (PAD) heavyweights against one another yielded an audience vote that went against the motion, “Bypass surgery is…
Endovascular showdown: CX 2024 sets the stage for BASIL-3 first-time data presentations
At the Charing Cross (CX) Symposium 2024 (23–25 April, London, UK), Andrew Bradbury (University of Birmingham, Birmingham, UK) and the BASIL-3 team of triallists will address the pressing question of which endovascular strategy wins in the disputed femoropopliteal segment. The…
BEST-CLI: A year down the road
A dedicated session at the 2023 VEITHsymposium (Nov. 14–18) in New York City aimed to unpack the ways in which clinical practice and attitudes in the field of chronic limb-threatening ischemia (CLTI) have changed since the BEST-CLI trial was published…
Obituary: Roger M. Greenhalgh (Feb. 6, 1941–Oct. 6, 2023)
Roger Malcolm Greenhalgh, MD, the surgeon internationally renowned for his unparalleled contribution to vascular education, training and research, died peacefully on Oct. 6. He was 82. At the time of his death, he was emeritus professor of surgery at Imperial…
The top 10 most popular Vascular Specialist stories of June 2023
Last month, Vascular Specialist garnered readers’ attention with an array of commentary on the BEST-CLI and BASIL-2 trials; the medical editor’s interview with vascular surgery’s ‘living legend’ Frank J. Veith, MD; the news of the death of Past SVS President…
VAM 2023 attendees have their say on the impact of BEST-CLI and BASIL-2 trials
As the vascular community continues to unpack the key learnings from two of the biggest trials to date in chronic limb threatening ischemia—BEST-CLI and BASIL-2—attendees of the 2023 Vascular Annual Meeting (VAM) in National Harbor, Maryland (June 14–17) told Vascular…
VAM attendees chime in on BEST-CLI and BASIL-2
VS@VAM journalist Will Date and videographer Jean-Philippe Bensoussan caught some VAM 2023 foot traffic outside the BEST-CLI and BASIL-2: Debate, Analysis and Implementation session last week to get their take on the two trials and how it has impacted their…
Special VAM session underscores ‘complementary’ nature of open and endovascular strategies in CLTI patients
A dedicated session at VAM 2023 saw speakers and delegates gather to debate, analyse and consider the implementation of the BEST-CLI and BASIL-2 randomized-controlled trials (RCTs). There was general agreement that the strategies are complementary, and that “picking the right…
BEST-CLI vs. BASIL-2: Different questions yield different answers
Medical editor Malachi Sheahan III, MD, takes a look at seemingly conflicting results from the landmark BEST-CLI and BASIL-2 trials, and asks what they really reveal. This past April, BASIL-2 chief investigator Andrew Bradbury, MD, presented trial results at the…
BASIL-2 and BEST-CLI: A tale of two limb trials
Optimal treatment of patients with chronic limb-threatening ischemia (CLTI) has been an ongoing debate within the vascular community, fueled by growing numbers of patients, evolving technologies, provider bias, and a lack of high-quality evidence. Few randomized controlled trials (RCTs) have…